A cell-therapy biotechnology company, Biostage Inc. (OTCQB: BSTG) (“Biostage” or the “Company”), has announced today the publication of a paper in the peer-reviewed Journal of Biomechanics. This published paper describes a study investigating the mechanical strength of regenerated esophageal tissues. Biostage is a biotechnology company with a successful first-in-human experience repairing the esophagus after cancer surgery. The company has FDA approval to commence a clinical trial for Biostage Esophageal Implant for acute esophageal diseases such as cancer.

The Biostage Esophageal Implant, formerly called Cellspan Esophageal Implant, stimulates the regeneration of new tissue after segmental resection of the thoracic esophagus. The paper published in the Journal describes a study testing the mechanical strength of the newly developed tissue. It will also flank native tissue around the area using a probe-burst pressure test on the explanted tissue at three-time points post-implantation. The Biostage Esophageal Implant helps bridge the proximal and distal native esophageal ends to help restore the circuit by stimulating a regeneration process.

This regeneration process progresses from a fibrovascular scar after 30 days to an epithelialized lumen at 90-days. A submucosal regeneration follows this, then the regeneration of a “laminated” adventitia with smooth muscle development in the 365-day cohort. The paper revealed that the burst strength of the regenerated tissues at all three-time points was comparable to the native tissue around the implant. It also noted that the pressure required to burst through the tissue increased with increasing post-surgery time.

Interim CEO of Biostage, David Green, said, “We are pleased to publish this paper in the Journal of Biomechanics. We believe this publication shows that the Biostage Esophageal Implant (BEI) stimulates the body to regenerate the esophagus and that the regenerated tissue is comparable in strength to the native esophagus.”

The Chief Scientific Officer of Biostage, Dr William Fodor, also added that the paper demonstrates that the regenerated tissue withstood pressure throughout the one year of study and that the study’s results helped establish a safe profile, a key component of the company’s approved IND.

Featured Image: Megapixl © bialasiewicz